


Reality Check: Antipsychotics

Coverage

Drugs


A review of atypical antipsychotic market access shows payer pharmacy benefit coverage by channel. For both commercial and HIX formularies, the amount of restricted lives increased significantly over the past two quarters, while Medicare coverage remained roughly even




Payers

Payers place top injectable antipsychotics on a combination of pharmacy benefit and medical benefit for U.S. lives. A look into reimbursement restrictions for payer pharmacy benefit lives shows that the presence of appropriate PA policies increased over the past 6 months, while step therapy policies remained nearly unchanged.

Step Therapies



Prior Authorizations



Key Players




Reality Check: Antipsychotics

Trends

Utilization in Pediatric Populations

Prescribing of antipsychotic pharmaceuticals to child patients has increased significantly over the recent past. This trend is evaluated by prescribers and clinicians presents an interesting challenge, with most safety and efficacy research surrounds adult patients.

[Via CoAction](#)



Prior Authorization Tests


Depending on a patient's geography and health plan, atypical antipsychotics often require some form of screenings/tests. However, recent research calls out of the lack of lipid screening for many antipsychotic patients.

[Via Science Daily](#)



Social Pharma

[Infographic via Kantar Health](#)



Reality Check: **Antipsychotics**

Key Findings

Drug Development Shifts Prescribing

Manufacturers approach the antipsychotics treatment landscape with novel therapies, primarily indicated for schizophrenia and bipolar disorder. Similar to what we experienced with introduction of long-acting injectable antipsychotics by big pharma, new players from the emerging pharma arena expect to shift market access distribution.


Increasingly Restrictive Commercial Coverage

Payers implement a variety of pharmacy benefit and medical benefit for injectable antipsychotics, whereas oral treatments process exclusively through pharmacy benefit. On the pharmacy benefit, PA requirements are significantly restrictive when they do exist, with roughly 2/3 situations including language that is restrictive to the FDA approved label.

Market Access Advantages by Geography

A review of market access at the state level reveals significant trends in product advantages. With brands facing intense competition from generic treatments, manufacturers invest in effective payer contracting for certain areas of the country.

State-run programs also help promote the use of certain brands, with the prevalence of Medicaid carve-outs. An analysis of a leading product's access by state shows that even top products face complex advantaged and disadvantaged coverage.



Characteristics

Indications

Schizophrenia

Bipolar Disorder

Major Depressive Disorder

Step Therapy Policies

For top payers implementing a step therapy requirement, single generic steps are the most common on the pharmacy benefit, at 55% of lives

PA Policies

When it comes to payer pharmacy benefit, roughly:

68% of atypical antipsychotic PAs are appropriate to the FDA approved label